Karyopharm Therapeutics
KPTI
KPTI
73 hedge funds and large institutions have $251M invested in Karyopharm Therapeutics in 2017 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 36 increasing their positions, 20 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
73
Holders Change
-7
Holders Change %
-8.75%
% of All Funds
1.82%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
36
Reduced
20
Closed
12
Calls
$1.24M
Puts
$816K
Net Calls
+$427K
Net Calls Change
-$823K
Top Buyers
| 1 |
BlackRock
New York
|
+$4.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.48M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$2.56M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$2.41M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$1.37M |
Top Sellers
| 1 |
JPMorgan Chase & Co
New York
|
-$4.37M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$3.46M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.13M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$962K |
| 5 |
SCA
Secor Capital Advisors
New York
|
-$781K |
